Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to chemotherapy, through progression-free survival (PFS). Apatinib will be given to patients with an efficacy assessment of stable disease (SD), partial response (PR), or complete response (CR) every 2 cycles. Patients were assigned to 500 mg/d apatinib continually until disease progression or intolerable toxicity or patients withdrawal of consent. The dose of apatinib may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg, and the sample size is about 30 individuals. Tumor tissue samples will be collected from each enrolled subjects before the start of treatment, and detected using next generation sequencing (NGS)-based comprehensive genomic profiling. The potential biomarkers in predicting apatinib efficacy or safety will be explored.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie zaawansowana lub rozprzestrzeniona rak żołądka
- •Wiek co najmniej 65 lat
- •Ogólny stan zdrowia umożliwiający leczenie (ECOG 0-2)
- •Brak wcześniejszego leczenia przeciwnowotworowego zaawansowanej choroby
- •Niemożliwość lub niechęć do chemioterapii
- •Co najmniej jeden widoczny guz mierzalny
- •Prawidłowa funkcja nerek, wątroby, serca i płuc
- •Spodziewana długość życia co najmniej 3 miesiące
✗ Disqualifies
- •Historia innego rodzaju nowotworu złośliwego
- •Niekontrolowane wysokie ciśnienie krwi pomimo leczenia
- •Niekontrolowana cukrzyca lub poważne choroby serca i mózgu
- •Tendencja do krwawień, leczenie przeciwzakrzepowe
- •Duża ilość płynu w opłucnej lub otrzewnej
- •Przerzuty do mózgu
- •Białko w moczu poza normą
- •Niemożliwość przyjmowania leku doustnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 65 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Trial contact
Yan Yang, M.D.,Ph.D
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.